Author:
Rutkowski Melanie R.,Green William R.
Reference174 articles.
1. Arnulf, B., Thorel, M., Poirot, Y., et al. 2004. Loss of the ex vivo but not the reinducible CD8+ T-cell response to Tax in human T-cell leukemia virus type 1-infected patients with adult T-cell leukemia/lymphoma. Leukemia 18:26–132.
2. Asquith, B., Mosley, A. J., Barfield, A., et al. 2005. A functional CD8+ cell assay reveals individual variation in CD8+ cell antiviral efficacy and explains differences in human T-lymphotropic virus type 1 proviral load. J. Gen. Virol. 86:1515–1523.
3. Aziz, D. C., Hanna, Z., Jolicoeur, P. 1989. Severe immunodeficiency disease induced by a defective murine leukaemia virus. Nature 338:505–508.
4. Azuma, H., Wegmann, K. W., Green, W. R. 1988. Correlations of in vivo growth of CTL-susceptible and -resistant variant tumor cell lines in CTL-responder AKR.H-2b:Fv-1b and -nonresponder AKR.H-2b mice. Cell. Immunol. 116:123–134.
5. Baba, E., Nakamura, M., Ohkuma, K., et al. 1995. A peptide-based human T cell leukemia virus type I vaccine containing T and B cell epitopes that induces high titers of neutralizing antibodies. J. Immunol. 154:399–412.